Objective: Breast cancer is the second leading cause of cancer death among American women. Risk factors for breast cancer include obesity, alcohol consumption, and estrogen therapy. In the present studies, we determine the simultaneous effects of these three risk factors on wingless int (Wnt)-1 mammary tumor growth.
B reast cancer is the second most frequent cancer afflicting American women and accounts for nearly 25% of all diagnosed cancers. 1 The American Cancer Society predicted approximately 207,000 new cases of invasive breast cancer in 2010, 40 ,000 of which would succumb to the disease. 1 Estrogen receptor > (ER->)Ypositive breast cancer is more prevalent among postmenopausal than premenopausal women. 2, 3 Modifiable risk factors for postmenopausal breast cancer, such as alcohol consumption, obesity, and estrogen plus progestogen therapy, have been shown to increase the risk of ER->Ypositive breast cancers. 4<6 Both obesity and alcohol consumption are established risk factors for breast cancer. 1,5,7<11 Postmenopausal obesity increases the risk of morbidity and mortality from breast cancer. 7, 8, 10, 11 Excess body weight accounts for nearly 30% to 50% of all breast cancer deaths. 11 Adipose tissue can produce a multitude of factors known to influence the carcinogenic process, such as estrogen, leptin, adiponectin, insulin like growth factor-1 (IGF-1), and cytokines. 12<15 Obesity increases the risk of developing ER->Ypositive cancers. 9 Obesity also increases the risk of developing fatty liver or hepatic steatosis. 16 Epidemiological studies have reinforced the positive association between alcohol consumption and breast cancer risk. 17 ER->Ypositive breast cancers are influenced by alcohol use, although the mechanism is unknown. 5 Alcohol consumption increases breast cancer risk in a dose-dependent manner: 10% for every drink consumed per day. 18 The hormonal status in postmenopausal women is also affected by alcohol: circulating blood estrogen levels increase in women who consume alcohol. 19<21 Moreover, chronic alcohol consumption increases the risk of developing hepatic steatosis. 22 Evidence suggests that both obesity and alcohol increase breast cancer risk via the hormone estrogen. 5,9,21,23<25 In premenopausal women, estrogen is produced largely by the ovaries. 26 However, after menopause, primary estrogen production shifts to the peripheral tissues (eg, adipose tissue) where aromatase converts androgen to estrogen. 14 As a result, obese postmenopausal women have higher estrogen levels than lean postmenopausal women. 24 Elevated estrogen levels are considered a risk factor for breast cancer. 25, 27, 28 Based on this phenomenon, it is reasonable to understand why obesity tends to increase the risk of estrogen-responsive cancers. 29 Alcohol consumption also increases systemic estrogen levels. 20, 21, 25, 30 Circulating blood estrogen levels may increase by as much as 20% in women who consume alcohol. 30 It is possible that alcohol increases systemic estrogen levels by increasing the expression level of aromatase. 31, 32 Studies also show that alcohol exposure increases the expression of ER-> in breast cancer cells. 31, 32 Therefore, alcohol increases not only systemic estrogen levels but also the expression of ER->, which may explain why breast cancer cells are more sensitive to estrogen in the presence of alcohol. This suggests that alcohol consumption in conjunction with estrogen therapy may increase breast cancer risk to a higher degree than either treatment alone. In fact, Chen et al 25 showed that alcohol, in combination with estrogen therapy, increases breast cancer risk to a greater extent than estrogen therapy or alcohol only.
Even though studies show that obesity, estrogen, and alcohol consumption can increase breast cancer risk, the simultaneous effects of these factors on mammary cancer have not been determined in an experimental setting. To assess the simultaneous effects of these three risk factors on tumor growth, we injected wingless int (Wnt)-1 mammary tumor cells subcutaneously into mice fed a 30% calorie-restricted (CR) or a low-(LF) or high-fat (HF) diet; the mice consumed either water or alcohol in the drinking water. To determine the combined effects of body weight, alcohol, and estrogen on tumor growth, control and obese mice consuming water and alcohol were implanted with pellets delivering estrogen and then injected with Wnt-1 tumor cells.
METHODS

Mouse husbandry and diets
All animal procedures were approved by the Austin Institutional Animal Care and Use Committee at the University of Texas. The mice were housed according to National Institutes of Health guidelines. One hundred eighty ovariectomized 6-week-old female C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The animals were maintained at 24-C on a 12-hour light/dark cycle. Mice were allowed to acclimate for 2 weeks, followed by randomization into treatment groups (nine groups, 20 mice per group). At this point, different diets were fed, and alcohol treatment commenced for 27 weeks. Mice were fed a 30% CR, LF (10% kilocalories from fat), or HF (60% kilocalories from fat) diet. The CR diet is a modified version of the LF diet in which the mice receive 70% of the average daily calories and 100% of the vitamins and minerals of the LF diet. All diets have been previously described and used to mimic lean, overweight, and obese postmenopausal women. 33 Water or 20% weight per volume alcohol in the water was given to the animals ad libitum throughout the entire study. Body weight, food consumption, and liquid consumption were measured weekly.
Pellet implantation
Estrogen (17A-estradiol) or placebo pellets were implanted 19 weeks into the study when the mice were 27 weeks old. Implantation occurred under the skin at the dorsal area between the neck and shoulder of the mice. We used estrogen pellets manufactured to deliver 0.72 mg of estrogen for 90 days (Innovative Research of America, Sarasota, FL). Therefore, the mice received estrogen/placebo treatment from the time the pellets were implanted until the end of the study when the mice were euthanized; this was approximately 8 weeks.
Wnt-1 transgenic mouse model of breast tumor growth
Mammary tumor cells were generated from mouse mammary tumor virusYWnt-1 transgenic mice on a C57BL/6J genetic background. Tumor cells were isolated from transgenic females as previously described. 34 Wnt-1 mouse tumors are ER->Ypositive like most human breast tumors in postmenopausal women. 35 For implantation, 1 Â 10 5 cells were implanted subcutaneously using 100 KL serum-free RPMI 1640 medium into the lower back, halfway between the middle of the back and the base of the tail at 22 weeks into the study when the mice were 30 weeks old. Once the tumors became palpable, tumor volume was determined three times a week with calipers by measuring the length, width, and depth of the tumor.
Body composition and uterine weight
Baseline percentage body fat was measured on unanesthetized mice using Echo magnetic resonance imaging (Echo Medical Systems, Houston, TX) when the mice were 8 weeks old. Percentage body fat and bone mineral density (BMD) were analyzed using dual-energy x-ray absorptiometry using a GE Lunar Piximus II densitometer (GE Lunar, Madison, WI) on the mouse carcasses at the end of the study when they were 35 weeks old. To evaluate uterine weight, mouse uteri were removed from the carcasses and weighed at the end of the study when the mice were 35 weeks old.
Serum analysis and blood chemistry
Serum was collected from the animals at baseline (24 wk old) and at the end of the study (35 wk old). Insulin (picograms per milliliter; Mercodia, Uppsala, Sweden) and 17A-estradiol (picograms per milliliter; Alpha Diagnostic, San Antonio, TX) enzyme-linked immunosorbent assay (ELISA) kits were used to measure serum insulin and estrogen, respectively. Similarly, serum adiponectin (nanograms per milliliter), vascular endothelial growth factor (VEGF; picograms per milliliter), leptin (picograms per milliliter), and IGF-1 (nanograms per milliliter) were also analyzed using ELISA kits (R&D Systems, Minneapolis, MN). Alanine aminotransferase (ALT) levels were measured in the serum using an ELISA kit (BIOO Scientific, Austin, TX). A nicotinamide adenine dinucleotide/reduced form of nicotinamide adenine dinucleotide kit (Sigma, St. Louis, MO) was used to quantify blood alcohol concentration (milligrams per deciliter). All kits were used according to manufacturer instructions.
Histology
Tissues were collected at sacrifice, at 35 weeks of age, and were fixed in 10% neutral buffered formalin for 24 hours followed by 70% ethanol until embedded in paraffin. The tissues were cut into 4-Km sections and stained with hematoxylin and eosin through standard procedures at the Histology and Tissue Processing Core at the University of Texas MD Anderson Science Park (Smithville, TX).
Statistical analysis
Statistical comparisons for all analyses (body composition, tumor volume, uterine weight, BMD, serum analysis) were determined using multivariate analysis of variance and post hoc comparison of the means using the Tukey honestly significant difference. SPSS version 15.0 software (SPSS Inc., Chicago, IL) was used to perform statistical evaluations. All results are presented as the mean T SEM, and statistical significance was considered at P G 0.05.
RESULTS
Body weight and percentage body fat were unaffected by alcohol and drastically modified by exogenous estrogen
At the start of the experiment, baseline body weights were comparable among all groups (P 9 0.05), as shown in Figure 1A . Baseline body weights were taken when the mice were 8 weeks old and immediately before diet and food regimens were implemented (depicted as week 1 on the graph). After administration of the different diet regimens, a nice shift in body weight was observed between CR, LF, and HF mice on water. Specifically, CR mice weighed the least, LF mice had an intermediate weight, and HF mice were the heaviest. Mice receiving the LF diet and water served as the control group for these experiments. Similar to the water group, mice receiving alcohol displayed the same trend in body weight; alcohol had no affect on body weight (P 9 0.05). These results were surprising as mice receiving alcohol consumed additional calories from alcohol, which provided 1.42 kcal/g; no differences in food consumption (P 9 0.05) were observed as highlighted in Table 1 . The blood alcohol concentration of mice consuming 20% alcohol are also depicted in Table 1 , which ranged from 57 to 90 mg/dL (0.057%-0.09%), levels equivalent to physiological levels known to increase breast cancer risk in women. 18, 36, 37 After exogenous estrogen supplementation, the HF group (P G 0.05), but not the CR group (P 9 0.05), underwent drastic weight loss, regardless of water or alcohol consumption. Exogenous estrogen modified body weight but had no affect on alcohol consumption.
Moreover, much like body weight, no differences in percentage body fat were seen between the groups at baseline (8 weeks old), as shown in Figure 1B . However, after treatment (35 weeks old), notable variations were detected between the CR and HF groups; CR mice had less percentage body fat than did HF mice for the placebo groups (P G 0.05). Alcohol consumption did not affect body fat levels. However, upon exogenous estrogen supplementation, percentage body fat drastically decreased, especially for mice in the HF groups compared with those in the placebo groups. 
Effect of exogenous estrogen on physiology
Estrogen has been shown to increase uterine weight and increase bone mineral density. 38 Because the animals used for the current study have been ovariectomized and lack endogenous estrogen, we decided to verify that the exogenous estrogen treatment was effective by analyzing the aforementioned physiological parameters in our mice. Figure 2A depicts serum estrogen levels at baseline (24 weeks of age) and after treatment (end of study, 35 weeks old) with estrogen and placebo pellets. No statistically significant difference in serum estrogen was noted among the groups before estrogen sup-plementation at baseline (P 9 0.05). However, after estrogen treatment, serum estrogen levels greatly increased compared with those in the placebo groups (P G 0.01). After estrogen treatment, uterine weight (35 weeks old, Fig. 2B ) significantly increased for both CR and HF mice given water and alcohol compared with the placebo group (P G 0.01). BMD also increased in the estrogen group compared with placebo ( Fig. 2C ; 35 weeks of age, P G 0.01). Collectively, the increased circulating blood estrogen levels, uterine weight, and BMD, along with the decreased percentage body fat suggest that estrogen implantation was successful. FIG. 2. Physiological effects of exogenous estrogen treatment. A: Levels of circulating serum estrogen. Estrogen levels were recorded at baseline when the mice were 24 weeks old and before the pellets were implanted. PostYestrogen treatment levels were evaluated at the end of the study when the mice were 35 weeks of age and after the pellets were implanted. There were 10 mice per group. B: Uterine weight was analyzed at the end of the study when the mice were 35 weeks old. There were 12 mice per group. C: Bone mineral density was evaluated when the mice were 35weeks of age. There were 20 mice per group. a Significantly different from corresponding placebo. HF, high fat; LF, low fat; CR, caloric restriction.
Obesity and alcohol promoted whereas exogenous estrogen suppressed tumor growth
As portrayed in Figure 3 , diet tended to promote mammary tumor growth. HF mice developed larger tumors than did CR mice; the difference was not significant for the water group (P = 0.153) but was significant for the alcohol group before estrogen treatment (P G 0.032). Alcohol treatment had a tendency to increase tumor volume in obese mice compared with mice given water for both the placebo and estrogen groups even though the difference was not significant (P 9 0.05). In contrast, alcohol did not affect the growth of CR tumors compared with water (P 9 0.05). Fascinatingly, compared with placebo, tumor growth was considerably suppressed in HF mice (P G 0.05) after estrogen pellet implantation. No distinctions were noticed for CR mice in either the estrogen or placebo group (P 9 0.05). Estrogen treatment inhibited the effects of both obesity (HF) and alcohol on tumor growth.
Effect of alcohol, obesity, and exogenous estrogen on growth factors
A multitude of growth factors, including but not limited to insulin, IGF-1, leptin, and VEGF, have been implicated in cancer. 39<47 Therefore, we decided to analyze the serum levels of these hormones to determine the role they may play in tumor growth in the present study. Serum insulin and IGF-1 levels increased in Figure 4A and B as body fat levels increased; CR mice had significantly lower levels of IGF-1 compared with HF mice after estrogen treatment (P G 0.01). Alcohol had no influence on insulin or IGF-1 compared with mice receiving water. However, supplementation of estrogen tended to significantly decrease the circulation of insulin in the blood of HF mice compared with placebo (P G 0.01). IGF-1 levels were also greatly diminished in CR mice after estrogen treatment (P G 0.05). Much like insulin and IGF-1, serum leptin levels increased with body adiposity as portrayed in Figure 5A (P G 0.05). Alcohol did not modify the effect of obesity on leptin expression. Nevertheless, serum leptin levels were dramatically reduced after the estrogen treatment of both CR (P G 0.05) and HF (P G 0.01) mice in contrast with placebo. Adiponectin levels, on the other hand, have been shown to inversely correlate with body fat. 48 Adiponectin levels in Figure 5B support this idea after treatment (35 weeks old): CR mice have higher serum adiponectin than HF mice in all groups except the alcohol/placebo group (P G 0.05). This was not the case at baseline (24 weeks old). In addition, estrogen treatment caused a down shift in adiponectin expression for both CR and HF animals versus placebo (P G 0.01). Finally, we determined the blood levels of the proangiogenic growth factor VEGF. Figure 6 shows that diet had no affect on VEGF levels after treatment. Among alcohol-fed mice, the HF diet compared with the CR diet stimulated VEGF levels after placebo treatment (P G 0.05). The addition of estrogen tended to block the effects of alcohol on VEGF levels in the HF mice after treatment, although the difference was not significant (P 9 0.05).
Alcohol and obesity negatively affected liver histopathology, which was reversed by exogenous estrogen Fatty liver disease, or hepatic steatosis, is commonly associated with alcohol consumption and obesity. 49<52 It is unclear how exogenous estrogen affects the disease. We qualitatively evaluated liver histology in the current study to determine whether estrogen has a deleterious or protective affect on hepatic steatosis. Figure 7A shows the induction of fatty liver with increasing adiposity as characterized by fat droplets in the hepatocytes. HF mice displayed more fatty liver than CR mice as shown in the literature. 53 Moreover, the condition seemed to worsen after alcohol consumption in HF animals compared with HF mice given water. Alcohol even had a negative effect on CR livers compared with the water group; however, this was not near the extent in HF animals. Importantly, estrogen treatment alleviated the fatty liver phenotype for all body weights and liquid groups and provided a protective effect. ALT is used as a marker of liver damage and FIG. 7. Effects of alcohol, obesity, and exogenous estrogen on liver histopathology. A: H&E-stained sections of fatty liver. Livers were fixed and analyzed when the mice were 35 weeks old. There were three mice per group, Â20 magnification, 100-Km bar. B: Levels of circulating ALT. There were 10 mice per group. PreYestrogen treatment ALT levels were recorded at baseline when the mice were 24 weeks old. PostYestrogen treatment levels were evaluated at the end of the study when the mice were 35 weeks of age. *Significantly different from corresponding CR. a Significantly different from corresponding placebo. H&E, hematoxylin and eosin; ALT, alanine aminotransferase; HF, high fat; LF, low fat; CR, caloric restriction.
FIG. 6. Levels of circulating VEGF. VEGF levels were measured at the end of the study when the mice were 35 weeks old. There were 10 mice per group. *Significantly different from corresponding CR. VEGF, vascular endothelial growth factor; HF, high fat; LF, low fat; CR, caloric restriction. overall liver health. 54 High levels of ALT are suggestive of fatty liver, as well as a myriad of other liver pathologies. To confirm the histology results, serum ALT levels were analyzed as depicted in Figure 7B . Serum ALT levels were consistent with the microscopic findings of the liver; ALT levels were higher in obese mice (P G 0.01), even higher in obese mice consuming alcohol (not significant), and ultimately suppressed to baseline levels (24 weeks of age; P 9 0.05) after estrogen treatment, especially in HF mice.
DISCUSSION
Postmenopausal women come in all sizes, lean, overweight, and obese, and many of them drink alcohol and even take estrogen to prevent the adverse effects of menopause. It is unclear whether body weight or exogenous estrogen modulates the effects of alcohol on breast cancer growth. To address this in an experimental setting, we determined the simultaneous effects of alcohol, obesity, and exogenous estrogen on tumor growth and fatty liver using mouse models in this study. Mice of different body weights (CR, LF, HF) consuming water or alcohol were injected subcutaneously with Wnt-1 cancer cells and implanted with placebo or estrogen pellets. Our results show that obesity promoted Wnt-1 tumor growth, which was ameliorated by estrogen supplementation. We also show that exogenous estrogen treatment resulted in significant weight loss in obese mice. Others have shown similar effects of exogenous estrogen on body weight. 55 We correlate the dramatic loss in body weight to Wnt-1 tumor growth suppression. Obese mice consuming alcohol tended to have elevated tumor growth compared with obese mice consuming water. However, the difference was not significant and therefore suggests that alcohol does not modulate the effects of body weight on tumor growth. Moreover, our results show that both obesity and alcohol consumption promoted fat accumulation in the liver and that exogenous estrogen completely blocked the accumulation of fat in the livers of obese and alcohol-consuming mice.
Here, alcohol consumption did not significantly modulate the effect of obesity on tumor growth. This does not rule out alcohol alone as a player in tumor growth. Evidence shows that alcohol accelerates tumor growth in mice, 56 and in cell culture studies, alcohol increases the metastatic potential of breast cancer cells in a dose-dependent manner. 57, 58 Moreover, alcohol and obesity are associated with high levels of hormones, including leptin and VEGF, which have been linked to breast cancer. 10,15,18,43,45,59<63 In cell culture studies, leptin promotes the proliferation and increases the invasiveness of breast cancer cells. 43, 44 Leptin also up-regulates aromatase activity, suggesting that leptin may affect breast cancer via estrogen. 59 Rene Gonzalez et al 60 demonstrated that blocking the effects of leptin using a pegylated leptin peptide receptor antagonist inhibited tumor growth in mice, suggesting that leptin plays an important role in breast cancer growth. 60 We reasoned that alcohol and obesity may influence mammary tumor growth via systemic hormones, such as lep-tin and estrogen. VEGF could also play a role. VEGF is a major player in angiogenesis, a process essential for tumor growth and metastasis. 45, 64, 65 We originally assumed that factors like VEGF, produced by adipose tissue, were associated with tumor growth; however, we cannot rule out the involvement of tumor-derived VEGF. VEGF levels were the highest in the HF placebo group receiving alcohol. This was interesting because alcohol had no effect on body weight nor body fat, suggesting that the effect must come from the tumor itself, rather than from the adipose tissue. Moreover, estrogen treatment decreased VEGF expression in these mice. These data are in contrast with the literature, which shows that estrogen increases serum levels of VEGF. 66 In our study, body weight and body fat significantly decreased after estrogen treatment, which was associated with a decrease in tumor growth. This suggests that decreased VEGF expression could correspond to tumor growth inhibition. 67 Much like alcohol consumption, obesity increases the risk of developing and dying from breast cancer in postmenopausal women. 7, 8, 10, 68, 69 Obesity can lead to multiple physiological alterations that can influence breast cancer susceptibility. Obesity is also associated with a plethora of comorbidities, such as hepatic steatosis. 16 Our results show that obesity promoted tumor growth. Moreover, obesity promoted liver steatosis. Serum insulin, IGF-1, leptin, and VEGF levels increased with increasing body weight. This suggests that obesity may affect tumor growth via these growth factors.
Estrogen is a steroid hormone produced predominantly by the ovaries in premenopausal women. 26 However, production shifts to peripheral tissues (eg, adipose tissue) in postmenopausal women, in whom aromatase converts androgen to estrogen. 26 Estrogen-producing cells, such as adipocytes, contain aromatase. 26 Obese postmenopausal women have higher estrogen levels than lean postmenopausal women because they have more adipose tissue and aromatase. 24 Elevated estrogen levels are considered a risk factor for breast cancer. 25, 27, 28 Surprisingly, estrogen treatment suppressed tumor growth in both CR and HF mice. This was unexpected because estrogen is a growth factor for breast cancer cells. The present data challenge the central dogma regarding estrogen and breast cancer; however, these effects of estrogen on tumor growth may be dependent on the presence of obesity. This notion is supported by findings from Nkhata et al, 55 who showed that estrogen treatment inhibited T47-D human breast cancer cell progression in obese mice. 55 Therefore, it is feasible that if estrogen treatment leads to a loss of body weight, then it may protect against breast cancer. On the other hand, the timing of estrogen supplementation may be the key to whether estrogen is a risk factor or a protector against breast cancer. For example, one study from the Women's Health Initiative highlighted the benefit of initiating estrogen therapy 5 years or more after menopause and emphasized the resultant decrease in breast cancer. 70 In most animal studies researchers do not consider this factor when designing experiments and supplement estrogen immediately before ovariectomy. 71<73 In doing this, they ignore physiological changes that occur after long-term estrogen deprivation, as seen in postmenopausal women. Others have shown under cell culture conditions that estrogen inhibited cell growth and induced the apoptosis (cell death) of MCF-7 breast cancer cells after long-term estrogen deprivation. 74 All of these studies highlight the delicate balance between hormone therapy timing and breast cancer susceptibility. Alternatively, it is possible that estrogen inhibits tumor growth but promotes breast cancer metastasis. 72 In our studies, we only evaluated primary tumor growth; thus, it is feasible that estrogen may have increased the metastatic ability of breast cancer cells, although it inhibits tumor growth.
Previous research has shown that estrogen treatment results in weight loss. 55 Therefore, the inhibition of tumor growth may be caused by weight loss after estrogen treatment and not by the estrogen treatment itself. In our studies, estrogen supplementation triggered a drastic decrease in body weight and percentage body fat in obese mice. What is more, circulating insulin and leptin levels were reduced after estrogen treatment. Therefore, the decrease in systemic growth factors, because of weight loss, may be responsible for the inhibition of tumor growth by estrogen treatment. The key factor for estrogen to inhibit tumor growth may be dependent on whether or not it promotes weight loss or, more specifically, loss of body fat, leading to a drastic decrease in systemic hormone levels (eg, leptin, insulin, and IGF-1).
Consistent with the literature, our studies show that both alcohol consumption and obesity promote liver steatosis (fatty liver). 49<52 Fatty liver is a reversible condition in which lipids accumulate in hepatocytes. 75 Fatty liver is strongly associated with obesity. 16, 76, 77 In our studies, consumption of alcohol by obese mice exacerbated liver steatosis to a greater extent than either alcohol or obesity alone. Liver steatosis was alleviated by estrogen treatment. Interestingly, fatty liver disease is more prevalent in men and postmenopausal women than in premenopausal women, suggesting that estrogen indeed is a protective factor against the development of liver steatosis. 78, 79 In addition, Ogawa et al 80 reported a dramatic induction of fatty liver in women with breast cancer treated with tamoxifen, an ER antagonist. 80 Therefore, these studies, along with our findings, support the notion that estrogen indeed may protect against the development of fatty liver. Although interesting, the data presented here are limited to the Wnt-1 allograft mouse model of breast cancer. The results reflect the effects of exogenous estrogen on this model and were restricted to 20% alcohol.
CONCLUSIONS
We show that both alcohol and obesity promoted tumor growth and fatty liver. Surprisingly, estrogen treatment inhibited the effects of obesity and alcohol consumption on tumor growth and fatty liver. This is the first study to show that estrogen is a protective factor against the effects of alcohol and obesity on mammary tumor growth and fatty liver development. It is interesting that estrogen can behave in such a dichotomous fashion as both a risk factor for breast cancer and suppressor of tumor growth in obese mice. Studies are warranted to determine whether certain estrogen therapies can indeed be used by postmenopausal women without leading to an increased risk of breast cancer.
